Catalyst

Slingshot members are tracking this event:

AstraZeneca (AZN) MYSTIC trial testing durvalumab and durva + treme for treatment of lung cancer, aiming for progression-free survival readout in mid-2017

Source Link:
https://www.astrazeneca.com/content/dam/az/PDF/Full_year_and_q4_2016_results/Full_Year_and_Q4_2016_Results_presentation.pdf

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
AZN Community voting in process
SIGN ME UP
I want to vote! LOG ME IN
Now!
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Jul 27, 2017
Occurred Source:
https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-reports-initial-results-from-the-ongoing-mystic-trial-in-stage-iv-lung-cancer-27072017.html
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Mystic, Durvalumab, Durva + Treme, Lung Cancer, Progression-free Survival
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.